Announcements Trials
Browse Landscape

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, B-Cell 2Recurrence 1Lymphoma, Follicular 1Dendritic Cell Sarcoma, Interdigitating 1

Interventions

Lenalidomide 4Rituximab 3zanubrutinib 2tafasitamab 2fludarabine 2Magnetic Resonance Spectroscopy 2Cyclophosphamide 2vorasidenib 1tislelizumab 1resiniferatoxin 1relmacabtagene autoleucel 1pomalidomide 1orelabrutinib 1obinutuzumab 1loncastuximab tesirine 1duvelisib 1Transurethral Resection of Bladder 1Temozolomide 1Standard of Care 1Spinal Puncture 1Specimen Handling 1Radiotherapy, Intensity-Modulated 1Prednisone 1Oxygen Consumption 1Interleukin-2 1Inhalation 1Furosemide 1Eflornithine 1Diet 1Bendamustine Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Lymphoma, Follicular × relmacabtagene autoleucel × Clear all
NCT06142188 2023-11-21

Relmacabtagene Autoleucel in Hematologic Malignancies

Shanghai Ming Ju Biotechnology Co., Ltd.

Not yet recruiting
150 enrolled
Lymphoid

Lymphoma, Follicular, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡